Loading…
The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity
Bacterial resistance toward available therapeutic agents has become a nightmare for the healthcare system, causing significant mortality as well as prolonged hospitalization, thereby needing the urgent attention of research groups working on antimicrobial drug development worldwide. Molecular hybrid...
Saved in:
Published in: | MedChemComm 2024-01, Vol.15 (1), p.234-253 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c393t-16be8c2c31f655a0a001b1e00a21e296db1c296dae5a30e17c01e715d339af873 |
---|---|
cites | cdi_FETCH-LOGICAL-c393t-16be8c2c31f655a0a001b1e00a21e296db1c296dae5a30e17c01e715d339af873 |
container_end_page | 253 |
container_issue | 1 |
container_start_page | 234 |
container_title | MedChemComm |
container_volume | 15 |
creator | Singh, Atamjit Kaur, Kirandeep Mohana, Pallvi Singh, Karanvir Sharma, Aman Prajapati, Jignesh Goswami, Dweipayan Khosla, Neha Kaur, Uttam Kaur, Rajanbir Kaur, Rajinder Rana, Abhineet Kour, Sandeep Ohri, Puja Arora, Saroj Chadha, Renu Singh Bedi, Preet Mohinder |
description | Bacterial resistance toward available therapeutic agents has become a nightmare for the healthcare system, causing significant mortality as well as prolonged hospitalization, thereby needing the urgent attention of research groups working on antimicrobial drug development worldwide. Molecular hybridization is a well-established tool for developing multifunctional compounds to tackle drug resistance. Inspired by the antibacterial profiles of isatin and thymol, along with the efficiency of a triazole linker in molecular hybridization, herein, we report the design, synthesis and antibacterial activity of a novel series of triazole tethered thymol-isatin hybrids. Most of the hybrids exhibited a broad-spectrum antibacterial efficacy against standard human pathogenic as well as clinically isolated multidrug-resistant bacterial strains listed in the WHO's 'priority pathogen' list and also in the ESKAPE group. Among them, hybrid compound
AS8
was the most effective against methicillin-resistant
Staphylococcus aureus
(MIC = 1.9 μM and MBC = 3.9 μM), exhibiting biofilm inhibitory potential.
AS8
exhibited dehydrosqualene synthase (CrtM) inhibitory potential in MRSA and decreased the production of virulence factor staphyloxanthin, which is one of the key mechanisms of its anti-MRSA efficacy, which was further supported by molecular docking and simulation studies. Moreover,
AS8
was found to be non-toxic and showed a potent
in vivo
antibacterial efficacy (90% survival at 10 mg kg
−1
) as well as a modulated immune response in the larva-based (
Galleria mellonella
) model of systemic infections. Overall findings confirmed that
AS8
can be a promising candidate or take the lead in the treatment and further drug development against drug-resistant infectious diseases, especially against MRSA infections.
Triazole-tethered isatin-thymol hybrids are developed for targeting multidrug-resistant bacterial strains with efficacy against MRSA acting
via
CrtM inhibition. The most active hybrid showed bactericidal and antibiofilm efficacy against MRSA and was capable of rescuing larvae from
in vivo
infection. |
doi_str_mv | 10.1039/d3md00580a |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_38283229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2918142116</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-16be8c2c31f655a0a001b1e00a21e296db1c296dae5a30e17c01e715d339af873</originalsourceid><addsrcrecordid>eNpdks1v1DAQxS0EolXphTvIEpcKKcVjN1n7hFYtH5VaIUE5WxPHaVwlcbCdRfvf47BlaXuakeY3z89-JuQ1sFNgQn1oxNAwVkqGz8ghrwQvZCX58wf9ATmO8Y4xxkuAqlQvyYGQXArO1SEZbzpLG7uxvZ8GOybqW5q67eD7wkVMbqTdtg6uiRQjrYPHpoiTNSnMA8UxuRpNssFhT_E2r0f626WOTj4tWgtQXH__saaZchuXtq_Iixb7aI_v6xH5-fnTzfnX4urbl8vz9VVhhBKpgKq20nAjoK3KEhkyBjVYxpCD5apqajBLQVuiYBZWhoFdQdkIobCVK3FEPu50p7kebGOym4C9noIbMGy1R6cfT0bX6Vu_0cAkU6LkWeHkXiH4X7ONSQ8uGtv3OFo_R80VqNUZCFgOe_cEvfNzGPP9FkrCGc_vnqn3O8oEH2Ow7d4NML1EqS_E9cXfKNcZfvvQ_x79F1wG3uyAEM1--v8viD-6kKSL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2918142116</pqid></control><display><type>article</type><title>The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity</title><source>Royal Society of Chemistry</source><creator>Singh, Atamjit ; Kaur, Kirandeep ; Mohana, Pallvi ; Singh, Karanvir ; Sharma, Aman ; Prajapati, Jignesh ; Goswami, Dweipayan ; Khosla, Neha ; Kaur, Uttam ; Kaur, Rajanbir ; Kaur, Rajinder ; Rana, Abhineet ; Kour, Sandeep ; Ohri, Puja ; Arora, Saroj ; Chadha, Renu ; Singh Bedi, Preet Mohinder</creator><creatorcontrib>Singh, Atamjit ; Kaur, Kirandeep ; Mohana, Pallvi ; Singh, Karanvir ; Sharma, Aman ; Prajapati, Jignesh ; Goswami, Dweipayan ; Khosla, Neha ; Kaur, Uttam ; Kaur, Rajanbir ; Kaur, Rajinder ; Rana, Abhineet ; Kour, Sandeep ; Ohri, Puja ; Arora, Saroj ; Chadha, Renu ; Singh Bedi, Preet Mohinder</creatorcontrib><description>Bacterial resistance toward available therapeutic agents has become a nightmare for the healthcare system, causing significant mortality as well as prolonged hospitalization, thereby needing the urgent attention of research groups working on antimicrobial drug development worldwide. Molecular hybridization is a well-established tool for developing multifunctional compounds to tackle drug resistance. Inspired by the antibacterial profiles of isatin and thymol, along with the efficiency of a triazole linker in molecular hybridization, herein, we report the design, synthesis and antibacterial activity of a novel series of triazole tethered thymol-isatin hybrids. Most of the hybrids exhibited a broad-spectrum antibacterial efficacy against standard human pathogenic as well as clinically isolated multidrug-resistant bacterial strains listed in the WHO's 'priority pathogen' list and also in the ESKAPE group. Among them, hybrid compound
AS8
was the most effective against methicillin-resistant
Staphylococcus aureus
(MIC = 1.9 μM and MBC = 3.9 μM), exhibiting biofilm inhibitory potential.
AS8
exhibited dehydrosqualene synthase (CrtM) inhibitory potential in MRSA and decreased the production of virulence factor staphyloxanthin, which is one of the key mechanisms of its anti-MRSA efficacy, which was further supported by molecular docking and simulation studies. Moreover,
AS8
was found to be non-toxic and showed a potent
in vivo
antibacterial efficacy (90% survival at 10 mg kg
−1
) as well as a modulated immune response in the larva-based (
Galleria mellonella
) model of systemic infections. Overall findings confirmed that
AS8
can be a promising candidate or take the lead in the treatment and further drug development against drug-resistant infectious diseases, especially against MRSA infections.
Triazole-tethered isatin-thymol hybrids are developed for targeting multidrug-resistant bacterial strains with efficacy against MRSA acting
via
CrtM inhibition. The most active hybrid showed bactericidal and antibiofilm efficacy against MRSA and was capable of rescuing larvae from
in vivo
infection.</description><identifier>ISSN: 2632-8682</identifier><identifier>ISSN: 2040-2503</identifier><identifier>EISSN: 2632-8682</identifier><identifier>EISSN: 2040-2511</identifier><identifier>DOI: 10.1039/d3md00580a</identifier><identifier>PMID: 38283229</identifier><language>eng</language><publisher>England: Royal Society of Chemistry</publisher><subject>Antibacterial activity ; Antibacterial agents ; Antimicrobial agents ; Biocompatibility ; Biofilms ; Chemistry ; Drug development ; Drug resistance ; Effectiveness ; Hybridization ; Hybrids ; Immune response ; Infectious diseases ; Methicillin ; Molecular docking ; Multidrug resistance ; Pharmacology ; Public health ; Staphylococcus infections ; Thymol ; Triazoles ; Virulence factors</subject><ispartof>MedChemComm, 2024-01, Vol.15 (1), p.234-253</ispartof><rights>This journal is © The Royal Society of Chemistry.</rights><rights>Copyright Royal Society of Chemistry 2024</rights><rights>This journal is © The Royal Society of Chemistry 2024 RSC</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-16be8c2c31f655a0a001b1e00a21e296db1c296dae5a30e17c01e715d339af873</citedby><cites>FETCH-LOGICAL-c393t-16be8c2c31f655a0a001b1e00a21e296db1c296dae5a30e17c01e715d339af873</cites><orcidid>0000-0003-3828-8110 ; 0000-0001-5439-8032 ; 0000-0001-7474-7068</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38283229$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singh, Atamjit</creatorcontrib><creatorcontrib>Kaur, Kirandeep</creatorcontrib><creatorcontrib>Mohana, Pallvi</creatorcontrib><creatorcontrib>Singh, Karanvir</creatorcontrib><creatorcontrib>Sharma, Aman</creatorcontrib><creatorcontrib>Prajapati, Jignesh</creatorcontrib><creatorcontrib>Goswami, Dweipayan</creatorcontrib><creatorcontrib>Khosla, Neha</creatorcontrib><creatorcontrib>Kaur, Uttam</creatorcontrib><creatorcontrib>Kaur, Rajanbir</creatorcontrib><creatorcontrib>Kaur, Rajinder</creatorcontrib><creatorcontrib>Rana, Abhineet</creatorcontrib><creatorcontrib>Kour, Sandeep</creatorcontrib><creatorcontrib>Ohri, Puja</creatorcontrib><creatorcontrib>Arora, Saroj</creatorcontrib><creatorcontrib>Chadha, Renu</creatorcontrib><creatorcontrib>Singh Bedi, Preet Mohinder</creatorcontrib><title>The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity</title><title>MedChemComm</title><addtitle>RSC Med Chem</addtitle><description>Bacterial resistance toward available therapeutic agents has become a nightmare for the healthcare system, causing significant mortality as well as prolonged hospitalization, thereby needing the urgent attention of research groups working on antimicrobial drug development worldwide. Molecular hybridization is a well-established tool for developing multifunctional compounds to tackle drug resistance. Inspired by the antibacterial profiles of isatin and thymol, along with the efficiency of a triazole linker in molecular hybridization, herein, we report the design, synthesis and antibacterial activity of a novel series of triazole tethered thymol-isatin hybrids. Most of the hybrids exhibited a broad-spectrum antibacterial efficacy against standard human pathogenic as well as clinically isolated multidrug-resistant bacterial strains listed in the WHO's 'priority pathogen' list and also in the ESKAPE group. Among them, hybrid compound
AS8
was the most effective against methicillin-resistant
Staphylococcus aureus
(MIC = 1.9 μM and MBC = 3.9 μM), exhibiting biofilm inhibitory potential.
AS8
exhibited dehydrosqualene synthase (CrtM) inhibitory potential in MRSA and decreased the production of virulence factor staphyloxanthin, which is one of the key mechanisms of its anti-MRSA efficacy, which was further supported by molecular docking and simulation studies. Moreover,
AS8
was found to be non-toxic and showed a potent
in vivo
antibacterial efficacy (90% survival at 10 mg kg
−1
) as well as a modulated immune response in the larva-based (
Galleria mellonella
) model of systemic infections. Overall findings confirmed that
AS8
can be a promising candidate or take the lead in the treatment and further drug development against drug-resistant infectious diseases, especially against MRSA infections.
Triazole-tethered isatin-thymol hybrids are developed for targeting multidrug-resistant bacterial strains with efficacy against MRSA acting
via
CrtM inhibition. The most active hybrid showed bactericidal and antibiofilm efficacy against MRSA and was capable of rescuing larvae from
in vivo
infection.</description><subject>Antibacterial activity</subject><subject>Antibacterial agents</subject><subject>Antimicrobial agents</subject><subject>Biocompatibility</subject><subject>Biofilms</subject><subject>Chemistry</subject><subject>Drug development</subject><subject>Drug resistance</subject><subject>Effectiveness</subject><subject>Hybridization</subject><subject>Hybrids</subject><subject>Immune response</subject><subject>Infectious diseases</subject><subject>Methicillin</subject><subject>Molecular docking</subject><subject>Multidrug resistance</subject><subject>Pharmacology</subject><subject>Public health</subject><subject>Staphylococcus infections</subject><subject>Thymol</subject><subject>Triazoles</subject><subject>Virulence factors</subject><issn>2632-8682</issn><issn>2040-2503</issn><issn>2632-8682</issn><issn>2040-2511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpdks1v1DAQxS0EolXphTvIEpcKKcVjN1n7hFYtH5VaIUE5WxPHaVwlcbCdRfvf47BlaXuakeY3z89-JuQ1sFNgQn1oxNAwVkqGz8ghrwQvZCX58wf9ATmO8Y4xxkuAqlQvyYGQXArO1SEZbzpLG7uxvZ8GOybqW5q67eD7wkVMbqTdtg6uiRQjrYPHpoiTNSnMA8UxuRpNssFhT_E2r0f626WOTj4tWgtQXH__saaZchuXtq_Iixb7aI_v6xH5-fnTzfnX4urbl8vz9VVhhBKpgKq20nAjoK3KEhkyBjVYxpCD5apqajBLQVuiYBZWhoFdQdkIobCVK3FEPu50p7kebGOym4C9noIbMGy1R6cfT0bX6Vu_0cAkU6LkWeHkXiH4X7ONSQ8uGtv3OFo_R80VqNUZCFgOe_cEvfNzGPP9FkrCGc_vnqn3O8oEH2Ow7d4NML1EqS_E9cXfKNcZfvvQ_x79F1wG3uyAEM1--v8viD-6kKSL</recordid><startdate>20240125</startdate><enddate>20240125</enddate><creator>Singh, Atamjit</creator><creator>Kaur, Kirandeep</creator><creator>Mohana, Pallvi</creator><creator>Singh, Karanvir</creator><creator>Sharma, Aman</creator><creator>Prajapati, Jignesh</creator><creator>Goswami, Dweipayan</creator><creator>Khosla, Neha</creator><creator>Kaur, Uttam</creator><creator>Kaur, Rajanbir</creator><creator>Kaur, Rajinder</creator><creator>Rana, Abhineet</creator><creator>Kour, Sandeep</creator><creator>Ohri, Puja</creator><creator>Arora, Saroj</creator><creator>Chadha, Renu</creator><creator>Singh Bedi, Preet Mohinder</creator><general>Royal Society of Chemistry</general><general>RSC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T5</scope><scope>7T7</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3828-8110</orcidid><orcidid>https://orcid.org/0000-0001-5439-8032</orcidid><orcidid>https://orcid.org/0000-0001-7474-7068</orcidid></search><sort><creationdate>20240125</creationdate><title>The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity</title><author>Singh, Atamjit ; Kaur, Kirandeep ; Mohana, Pallvi ; Singh, Karanvir ; Sharma, Aman ; Prajapati, Jignesh ; Goswami, Dweipayan ; Khosla, Neha ; Kaur, Uttam ; Kaur, Rajanbir ; Kaur, Rajinder ; Rana, Abhineet ; Kour, Sandeep ; Ohri, Puja ; Arora, Saroj ; Chadha, Renu ; Singh Bedi, Preet Mohinder</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-16be8c2c31f655a0a001b1e00a21e296db1c296dae5a30e17c01e715d339af873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibacterial activity</topic><topic>Antibacterial agents</topic><topic>Antimicrobial agents</topic><topic>Biocompatibility</topic><topic>Biofilms</topic><topic>Chemistry</topic><topic>Drug development</topic><topic>Drug resistance</topic><topic>Effectiveness</topic><topic>Hybridization</topic><topic>Hybrids</topic><topic>Immune response</topic><topic>Infectious diseases</topic><topic>Methicillin</topic><topic>Molecular docking</topic><topic>Multidrug resistance</topic><topic>Pharmacology</topic><topic>Public health</topic><topic>Staphylococcus infections</topic><topic>Thymol</topic><topic>Triazoles</topic><topic>Virulence factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singh, Atamjit</creatorcontrib><creatorcontrib>Kaur, Kirandeep</creatorcontrib><creatorcontrib>Mohana, Pallvi</creatorcontrib><creatorcontrib>Singh, Karanvir</creatorcontrib><creatorcontrib>Sharma, Aman</creatorcontrib><creatorcontrib>Prajapati, Jignesh</creatorcontrib><creatorcontrib>Goswami, Dweipayan</creatorcontrib><creatorcontrib>Khosla, Neha</creatorcontrib><creatorcontrib>Kaur, Uttam</creatorcontrib><creatorcontrib>Kaur, Rajanbir</creatorcontrib><creatorcontrib>Kaur, Rajinder</creatorcontrib><creatorcontrib>Rana, Abhineet</creatorcontrib><creatorcontrib>Kour, Sandeep</creatorcontrib><creatorcontrib>Ohri, Puja</creatorcontrib><creatorcontrib>Arora, Saroj</creatorcontrib><creatorcontrib>Chadha, Renu</creatorcontrib><creatorcontrib>Singh Bedi, Preet Mohinder</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>MedChemComm</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singh, Atamjit</au><au>Kaur, Kirandeep</au><au>Mohana, Pallvi</au><au>Singh, Karanvir</au><au>Sharma, Aman</au><au>Prajapati, Jignesh</au><au>Goswami, Dweipayan</au><au>Khosla, Neha</au><au>Kaur, Uttam</au><au>Kaur, Rajanbir</au><au>Kaur, Rajinder</au><au>Rana, Abhineet</au><au>Kour, Sandeep</au><au>Ohri, Puja</au><au>Arora, Saroj</au><au>Chadha, Renu</au><au>Singh Bedi, Preet Mohinder</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity</atitle><jtitle>MedChemComm</jtitle><addtitle>RSC Med Chem</addtitle><date>2024-01-25</date><risdate>2024</risdate><volume>15</volume><issue>1</issue><spage>234</spage><epage>253</epage><pages>234-253</pages><issn>2632-8682</issn><issn>2040-2503</issn><eissn>2632-8682</eissn><eissn>2040-2511</eissn><abstract>Bacterial resistance toward available therapeutic agents has become a nightmare for the healthcare system, causing significant mortality as well as prolonged hospitalization, thereby needing the urgent attention of research groups working on antimicrobial drug development worldwide. Molecular hybridization is a well-established tool for developing multifunctional compounds to tackle drug resistance. Inspired by the antibacterial profiles of isatin and thymol, along with the efficiency of a triazole linker in molecular hybridization, herein, we report the design, synthesis and antibacterial activity of a novel series of triazole tethered thymol-isatin hybrids. Most of the hybrids exhibited a broad-spectrum antibacterial efficacy against standard human pathogenic as well as clinically isolated multidrug-resistant bacterial strains listed in the WHO's 'priority pathogen' list and also in the ESKAPE group. Among them, hybrid compound
AS8
was the most effective against methicillin-resistant
Staphylococcus aureus
(MIC = 1.9 μM and MBC = 3.9 μM), exhibiting biofilm inhibitory potential.
AS8
exhibited dehydrosqualene synthase (CrtM) inhibitory potential in MRSA and decreased the production of virulence factor staphyloxanthin, which is one of the key mechanisms of its anti-MRSA efficacy, which was further supported by molecular docking and simulation studies. Moreover,
AS8
was found to be non-toxic and showed a potent
in vivo
antibacterial efficacy (90% survival at 10 mg kg
−1
) as well as a modulated immune response in the larva-based (
Galleria mellonella
) model of systemic infections. Overall findings confirmed that
AS8
can be a promising candidate or take the lead in the treatment and further drug development against drug-resistant infectious diseases, especially against MRSA infections.
Triazole-tethered isatin-thymol hybrids are developed for targeting multidrug-resistant bacterial strains with efficacy against MRSA acting
via
CrtM inhibition. The most active hybrid showed bactericidal and antibiofilm efficacy against MRSA and was capable of rescuing larvae from
in vivo
infection.</abstract><cop>England</cop><pub>Royal Society of Chemistry</pub><pmid>38283229</pmid><doi>10.1039/d3md00580a</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0003-3828-8110</orcidid><orcidid>https://orcid.org/0000-0001-5439-8032</orcidid><orcidid>https://orcid.org/0000-0001-7474-7068</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2632-8682 |
ispartof | MedChemComm, 2024-01, Vol.15 (1), p.234-253 |
issn | 2632-8682 2040-2503 2632-8682 2040-2511 |
language | eng |
recordid | cdi_pubmed_primary_38283229 |
source | Royal Society of Chemistry |
subjects | Antibacterial activity Antibacterial agents Antimicrobial agents Biocompatibility Biofilms Chemistry Drug development Drug resistance Effectiveness Hybridization Hybrids Immune response Infectious diseases Methicillin Molecular docking Multidrug resistance Pharmacology Public health Staphylococcus infections Thymol Triazoles Virulence factors |
title | The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A05%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20development%20of%20thymol-isatin%20hybrids%20as%20broad-spectrum%20antibacterial%20agents%20with%20potent%20anti-MRSA%20activity&rft.jtitle=MedChemComm&rft.au=Singh,%20Atamjit&rft.date=2024-01-25&rft.volume=15&rft.issue=1&rft.spage=234&rft.epage=253&rft.pages=234-253&rft.issn=2632-8682&rft.eissn=2632-8682&rft_id=info:doi/10.1039/d3md00580a&rft_dat=%3Cproquest_pubme%3E2918142116%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c393t-16be8c2c31f655a0a001b1e00a21e296db1c296dae5a30e17c01e715d339af873%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2918142116&rft_id=info:pmid/38283229&rfr_iscdi=true |